{"id":"hizentra","rwe":[],"tags":[],"trials":[],"_chembl":null,"aliases":["IgPro20","Immune Globulin Subcutaneous (Human), 20% Liquid","subcutaneous gammaglobulin therapy"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":{"setId":"7b58f5ff-0316-49a3-b585-1f6003ddb953","title":"HIZENTRA (HUMAN IMMUNOGLOBULIN G) LIQUID [CSL BEHRING AG]"},"ecosystem":[],"_scrapedAt":"2026-03-28T00:23:51.935Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06976476","phase":"PHASE2","title":"Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-05-08","conditions":"Multiple Myeloma, Hypogammaglobulinemia, Hypogammaglobulinemia, Acquired","enrollment":100},{"nctId":"NCT06565078","phase":"","title":"A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary Immunodeficiency","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-02-17","conditions":"Primary Immunodeficiency Diseases (PID)","enrollment":100},{"nctId":"NCT05584631","phase":"PHASE1","title":"IVIG vs SCIG in CIDP","status":"RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2022-09-11","conditions":"CIDP, Immunoglobulin Deficiency, Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":20},{"nctId":"NCT04044690","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)","status":"TERMINATED","sponsor":"CSL Behring","startDate":"2019-10-21","conditions":"Dermatomyositis","enrollment":134},{"nctId":"NCT06524739","phase":"PHASE3","title":"Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS","status":"TERMINATED","sponsor":"CSL Behring","startDate":"2024-08-28","conditions":"Post-COVID Postural Orthostatic Tachycardia Syndrome","enrollment":16},{"nctId":"NCT06150534","phase":"","title":"At-Home Subcutaneous Immunoglobulin Replacement Therapy Using Alexa Skill","status":"COMPLETED","sponsor":"Takeda","startDate":"2023-12-27","conditions":"Primary Immunodeficiency Diseases (PID)","enrollment":22},{"nctId":"NCT04728425","phase":"PHASE2","title":"Subcutaneous Immunoglobulin for Myasthenia Gravis","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2020-08-28","conditions":"Myasthenia Gravis","enrollment":30},{"nctId":"NCT05193552","phase":"PHASE4","title":"Usage of Spirometry in Managing IgG Therapy in CVID with Airway Disease","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2024-01-15","conditions":"Common Variable Immunodeficiency","enrollment":22},{"nctId":"NCT04672733","phase":"","title":"Hizentra® in Inflammatory Neuropathies - pHeNIx Study","status":"RECRUITING","sponsor":"CSL Behring","startDate":"2022-06-10","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":100},{"nctId":"NCT02465359","phase":"NA","title":"Subcutaneous Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","status":"COMPLETED","sponsor":"University of South Florida","startDate":"2014-09","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":15},{"nctId":"NCT03919773","phase":"PHASE1, PHASE2","title":"IVIG (Gamunex-C) Treatment Study for POTS Subjects","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2018-10-29","conditions":"Postural Tachycardia Syndrome","enrollment":30},{"nctId":"NCT04589299","phase":"PHASE4","title":"Subcutaneous Immunoglobulin in De-novo CIDP (SIDEC)","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2020-06-04","conditions":"CIDP - Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":60},{"nctId":"NCT02915263","phase":"PHASE2","title":"The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes","status":"TERMINATED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2017-09-11","conditions":"Diabetes Complications, Diabetes Mellitus, Diabetic Neuropathies","enrollment":13},{"nctId":"NCT04137224","phase":"PHASE2","title":"Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2019-09-19","conditions":"Diffuse Cutaneous Systemic Sclerosis","enrollment":27},{"nctId":"NCT03401073","phase":"PHASE2","title":"IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2018-09-01","conditions":"Small Fiber Neuropathy, Idiopathic Peripheral Neuropathy","enrollment":20},{"nctId":"NCT05764993","phase":"PHASE2","title":"Prevalence of Humoral Dysfunction in Pts With Frequent Exacerbations of COPD, and the Effect of SCIgR for Prevention","status":"UNKNOWN","sponsor":"Rochester General Hospital","startDate":"2023-06-01","conditions":"COPD Exacerbation Acute","enrollment":40},{"nctId":"NCT04561115","phase":"PHASE3","title":"A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2020-09-02","conditions":"Primary Immunodeficiency","enrollment":33},{"nctId":"NCT02774239","phase":"PHASE3","title":"A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG)","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2014-10","conditions":"Myasthenia Gravis","enrollment":26},{"nctId":"NCT03116347","phase":"PHASE4","title":"Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2017-05-30","conditions":"Primary Immunodeficiency Diseases (PID)","enrollment":42},{"nctId":"NCT04450654","phase":"PHASE2","title":"Monotherapy IVIG Gamunex-C for HMG-CoA Reductase Auto-Antibody Positive Necrotizing Myopathy Treatment (The MIGHT Trial)","status":"WITHDRAWN","sponsor":"University of Washington","startDate":"2022-05","conditions":"Immune-Mediated Necrotizing Myopathy","enrollment":""},{"nctId":"NCT04480424","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2020-09-17","conditions":"COVID-19","enrollment":100},{"nctId":"NCT04636502","phase":"","title":"Retrospective, Observational Chart Review Study Conducted in Poland to Document the Management and Clinical Outcome of CUVITRU and HYQVIA in Pediatric Participants (< 18 Years) With Primary Immunodeficiency (PID)","status":"COMPLETED","sponsor":"Shire","startDate":"2021-02-08","conditions":"Primary Immunodeficiencies (PID)","enrollment":96},{"nctId":"NCT03737617","phase":"PHASE4","title":"Immunoglobulin Replacement Therapy for Immunoglobulin G Subclass 2 Deficient Patients With Bronchiectasis","status":"WITHDRAWN","sponsor":"University of Edinburgh","startDate":"2022-08-05","conditions":"Bronchiectasis, Immunoglobulin Subclass Deficiency","enrollment":""},{"nctId":"NCT02100969","phase":"PHASE2","title":"Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis","status":"COMPLETED","sponsor":"Mazen Dimachkie, MD","startDate":"2015-05","conditions":"Myasthenia Gravis","enrollment":23},{"nctId":"NCT03211065","phase":"PHASE2, PHASE3","title":"Humoral Immunodeficiency With Rituximab and Therapy With Subcutaneous Ig","status":"COMPLETED","sponsor":"Rochester General Hospital","startDate":"2017-07-21","conditions":"Secondary Immune Deficiency","enrollment":16},{"nctId":"NCT03716700","phase":"","title":"Real-world CANadian CUvitru Non-Interventional Study in Subjects Transitioning From Subcutaneous Immunoglobulin (CANCUN)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2018-09-24","conditions":"Primary Immunodeficiency Diseases (PID)","enrollment":126},{"nctId":"NCT03730129","phase":"PHASE2, PHASE3","title":"Humoral Immunodeficiency in CLL and Therapy With Subcutaneous Ig","status":"COMPLETED","sponsor":"Rochester General Hospital","startDate":"2018-11-05","conditions":"Secondary Immune Deficiency Disorder","enrollment":20},{"nctId":"NCT03033745","phase":"PHASE4","title":"Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2017-02-01","conditions":"Primary Immunodeficiency","enrollment":49},{"nctId":"NCT02697292","phase":"PHASE3","title":"IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2016-02","conditions":"Autoimmune Epilepsy","enrollment":17},{"nctId":"NCT01854827","phase":"PHASE1, PHASE2","title":"Safety Study of Intravenous Immunoglobulin (IVIG) Post-Portoenterostomy in Infants With Biliary Atresia","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2013-10","conditions":"Biliary Atresia","enrollment":30},{"nctId":"NCT03401268","phase":"NA","title":"Subcutaneous Ig in Allogeneic Stem Cell Transplant Recipients","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2018-02-01","conditions":"Hypogammaglobulinemia","enrollment":20},{"nctId":"NCT01828294","phase":"PHASE1","title":"Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis","status":"TERMINATED","sponsor":"St. Louis University","startDate":"2011-10","conditions":"Myasthenia Gravis","enrollment":4},{"nctId":"NCT02027701","phase":"PHASE3","title":"Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2014-07-30","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Polyradiculoneuropathy, Chronic Inflammatory Demyelinating","enrollment":82},{"nctId":"NCT01545076","phase":"PHASE3","title":"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2012-03","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy, Polyradiculoneuropathy","enrollment":208},{"nctId":"NCT02271165","phase":"EARLY_PHASE1","title":"Subcutaneous Immunoglobulin (Hizentra) in Patients With Dermatomyositis: A Proof of Concept Study","status":"TERMINATED","sponsor":"Thomas Jefferson University","startDate":"2014-11","conditions":"Dermatomyositis","enrollment":2},{"nctId":"NCT02711228","phase":"PHASE4","title":"Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2016-03-15","conditions":"Primary Immune Deficiency, Secondary Immune Deficiency","enrollment":26},{"nctId":"NCT02042027","phase":"PHASE1","title":"Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions","status":"WITHDRAWN","sponsor":"University of Utah","startDate":"2014-07","conditions":"Corneal Neovascularization, Corneal Graft Failure, Anterior Segment Inflammation","enrollment":""},{"nctId":"NCT02111590","phase":"","title":"Immunoglobulin Dosage and Administration Form in CIDP and MMN","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2014-01","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy, Multifocal Motor Neuropathy, Hemolytic Anemia","enrollment":36},{"nctId":"NCT01465958","phase":"PHASE4","title":"Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2011-11","conditions":"Primary Immunodeficiency","enrollment":12},{"nctId":"NCT01199705","phase":"PHASE3","title":"Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2010-09","conditions":"Primary Immune Deficiency","enrollment":25},{"nctId":"NCT01461018","phase":"PHASE3","title":"Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Primary Immunodeficiency (Japan Study)","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2011-10","conditions":"Primary Immune Deficiency","enrollment":22},{"nctId":"NCT00719680","phase":"PHASE3","title":"Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2008-06","conditions":"Primary Immune Deficiency","enrollment":21},{"nctId":"NCT00751621","phase":"PHASE3","title":"Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2008-08","conditions":"Primary Immunodeficiency (PID)","enrollment":40},{"nctId":"NCT01458171","phase":"PHASE3","title":"Follow-up Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2011-04","conditions":"Primary Immune Deficiency Disorder","enrollment":23},{"nctId":"NCT00419341","phase":"PHASE3","title":"Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2006-11","conditions":"Primary Immune Deficiency","enrollment":49},{"nctId":"NCT01354587","phase":"NA","title":"Evaluation of Efficacy and Tolerability of Hizentra®","status":"UNKNOWN","sponsor":"University of South Florida","startDate":"2010-10","conditions":"Primary Immunodeficiency Disorders","enrollment":50},{"nctId":"NCT00542997","phase":"PHASE3","title":"Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2007-09","conditions":"Common Variable Immunodeficiency, X-linked Agammaglobulinemia, Autosomal Recessive Agammaglobulinemia","enrollment":51}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Hizentra","genericName":"Hizentra","companyName":"CSL Behring","companyId":"csl-behring","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":3,"withResults":1},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}